Wockhardt Ltd

₹ 1,921 -7.33%

05 Jun - close price

wockhardt.com BSE: 532300 NSE: WOCKPHARMA

About

Wockhardt is a global pharmaceutical and biotechnology organization engaged in manufacturing finished dosage formulations, injectables, biopharmaceuticals, orals and topicals (creams and ointments). ^[1]

Key Points

Market Position
The company is amongst the top 3 Indian generic companies in the UK and the 6th largest generic supplier in the retail and hospital channels in Ireland. It is the No. 1 Methycobalamin brand in India. ^[1]

Website BSE NSE

Market Cap ₹ 31,213 Cr.
Current Price ₹ 1,921
High / Low ₹ 2,422 / 1,087
Stock P/E 110
Book Value ₹ 304
Dividend Yield 0.00 %
ROCE 7.55 %
ROE 6.11 %
Face Value ₹ 5.00

Add ratio to table

Edit ratios

Pros

Cons

Stock is trading at 6.32 times its book value
The company has delivered a poor sales growth of 4.49% over past five years.
Company has a low return on equity of -1.43% over last 3 years.
Promoter holding has decreased over last 3 years: -10.2%
Working capital days have increased from -27.3 days to 89.3 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE 500 BSE Healthcare Nifty 500 Nifty Pharma Nifty500 Shariah Nifty Smallcap 100 Nifty High Beta 50 BSE SmallCap Select Index BSE 250 SmallCap Index BSE 400 MidSmallCap Index Nifty MidSmallcap 400 Nifty Smallcap 50 Nifty Smallcap 250 Nifty 500 Multicap 50:25:25 Nifty Total Market Nifty MidSmall Healthcare Nifty500 Multicap India Manufacturing 50:30:20 Nifty500 Equal Weight Nifty500 LargeMidSmall Equal-Cap Weighted BSE 1000 Nifty500 Healthcare Nifty Smallcap 500

Edit Columns

Loading peers table ...

Detailed Comparison with:

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
	678	644	753	701	700	739	809	721	743	738	782	888	965
	675	628	681	664	759	648	699	593	679	666	604	711	740
Operating Profit	3	16	72	37	-59	91	110	128	64	72	178	177	225
OPM %	0%	2%	10%	5%	-8%	12%	14%	18%	9%	10%	23%	20%	23%
	-64	0	24	8	10	30	9	8	15	-77	21	15	67
Interest	76	79	76	77	73	73	73	60	48	48	55	60	50
Depreciation	56	55	55	55	58	54	55	55	53	56	53	65	53
Profit before tax	-193	-118	-35	-87	-180	-6	-9	21	-22	-109	91	67	189
Tax %	23%	15%	109%	-1%	-2%	167%	78%	5%	105%	-1%	10%	9%	13%
	-237	-136	-73	-86	-177	-16	-16	20	-45	-108	82	61	164
EPS in Rs	-14.44	-9.30	-5.34	-5.76	-11.02	-0.91	-1.43	0.86	-1.54	-5.54	4.80	3.63	10.22
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	4,482	4,453	4,015	3,937	3,566	2,844	2,708	3,230	2,651	2,798	3,012	3,373
	3,772	3,959	4,002	3,935	3,604	2,725	2,771	2,932	2,550	2,707	2,619	2,721
Operating Profit	709	494	13	2	-38	119	-63	298	101	91	393	652
OPM %	16%	11%	0%	0%	-1%	4%	-2%	9%	4%	3%	13%	19%
	67	66	114	-238	116	133	975	-163	-172	17	62	26
Interest	55	129	225	255	265	276	249	299	302	305	254	213
Depreciation	145	142	149	150	164	224	246	247	251	223	217	227
Profit before tax	575	289	-247	-641	-351	-247	417	-411	-624	-420	-16	238
Tax %	28%	13%	-9%	4%	-38%	-82%	-65%	-32%	-0%	12%	256%	16%
	413	252	-226	-667	-217	-43	689	-279	-621	-472	-57	199
EPS in Rs	28.30	17.45	-13.62	-42.30	-13.52	-4.81	47.64	-16.94	-38.80	-30.18	-2.89	13.11
Dividend Payout %	54%	0%	-56%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Compounded Sales Growth
10 Years:	-3%
5 Years:	4%
3 Years:	8%
TTM:	12%

Compounded Profit Growth
10 Years:	1%
5 Years:	-19%
3 Years:	43%
TTM:	704%

Stock Price CAGR
10 Years:	8%
5 Years:	26%
3 Years:	124%
1 Year:	28%

Return on Equity
10 Years:	-2%
5 Years:	-3%
3 Years:	-1%
Last Year:	6%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	55	55	55	55	55	55	55	72	72	77	81	81
Reserves	3,362	3,720	3,281	2,797	2,619	2,616	3,321	3,777	3,282	3,282	4,272	4,859
	2,309	2,677	4,160	3,748	3,375	3,582	2,673	2,198	2,184	2,356	2,021	2,233
	1,213	1,622	1,486	1,528	1,764	1,894	1,695	2,168	2,113	1,899	1,726	1,442
Total Liabilities	6,939	8,074	8,982	8,128	7,813	8,148	7,744	8,215	7,651	7,614	8,100	8,615
	2,123	2,809	2,773	2,888	3,058	3,502	3,343	3,462	3,042	2,881	2,736	4,499
CWIP	1,007	1,036	1,244	1,433	1,445	1,585	1,379	1,342	1,539	1,722	2,033	671
Investments	341	0	563	214	0	0	0	0	0	0	422	412
	3,468	4,228	4,403	3,593	3,309	3,060	3,022	3,411	3,070	3,011	2,909	3,033
Total Assets	6,939	8,074	8,982	8,128	7,813	8,148	7,744	8,215	7,651	7,614	8,100	8,615

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	355	-42	-269	68	183	649	-287	413	153	219	-22	390
	-222	-105	-684	635	93	-147	1,471	-204	-118	-138	-780	-241
	-76	193	1,254	-769	-776	-680	-1,171	-71	-315	334	409	-54
Net Cash Flow	57	46	301	-66	-500	-178	13	138	-280	415	-393	95
Free Cash Flow	-76	-105	-678	-238	127	486	-452	202	23	69	-377	76
CFO/OP	73%	-8%	-1,887%	4,697%	-583%	560%	270%	171%	162%	274%	-13%	63%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	60	91	94	89	130	159	124	104	110	81	80	64
Inventory Days	250	249	243	174	183	209	257	222	216	201	234	286
Days Payable	136	144	117	122	187	272	186	265	285	240	191	182
Cash Conversion Cycle	175	196	220	141	126	97	195	60	41	41	123	168
Working Capital Days	14	52	36	-56	-51	-171	-133	-116	-186	-148	-23	89
ROCE %	10%	7%	-1%	-1%	-1%	-1%	-3%	1%	-0%	-1%	4%	8%

Insights

In beta

Mar 2015

Mar 2016

Mar 2017

Mar 2018

Mar 2020

Mar 2021

Mar 2022

Mar 2023

Mar 2024

Mar 2025

Emerging Markets Sales Contribution
%

xx	x	x	xx	xx	xx	xx	xx	xx	xx
xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
xx	xx	xx	xx	xx	xx	xx	xx	xx	xx
x	x	x	x		x	x	x	x	x
x,xxx	x,xxx	x,xxx	x,xxx	x,xxx	x,xxx	x,xxx	x,xxx	x,xxx
					xx	xx	xx		xx
		xxx			xxx	xxx	xxx
					xx	xx	xx		xx
							xx,xxx	xx,xxx	xxx,xxx
									xx
									xxx
									xx
				x.xx	x.xx	x.xx		x.xx

Please log in to see hidden values.

India Sales Contribution
%

Manufacturing Facilities Overall
Count

Number of Programs granted QIDP status by US FDA
Count

Total Employees
Count

Scientists within Drug Discovery Team with PhDs
Count

Total Scientists employed
Count

UK Sales Contribution
%

Patients treated with EMROK/EMROK O (Cumulative)
Patients

Compassionate use lives saved (ZAYNICH)
Lives

Drug Discovery Team
Total Personnel

Market Share of EMROK in target segment
%

R&D Expenditure (Percentage of Turnover)
% ・Standalone data

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

2 Recently

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
	58.40%	55.14%	54.93%	51.60%	51.99%	51.99%	49.09%	49.09%	49.09%	49.09%	49.09%	49.09%
	2.60%	3.03%	4.18%	5.49%	5.94%	6.70%	6.54%	6.82%	7.29%	7.10%	7.00%	7.09%
	0.18%	0.21%	0.30%	4.82%	4.45%	5.08%	9.82%	10.58%	11.00%	11.00%	10.55%	10.96%
	0.00%	0.00%	0.00%	0.01%	0.01%	0.02%	0.02%	0.02%	0.02%	0.02%	0.02%	0.04%
	38.83%	41.62%	40.59%	38.06%	37.62%	36.21%	34.54%	33.50%	32.60%	32.79%	33.36%	32.84%
No. of Shareholders	1,78,915	1,72,989	1,61,813	1,46,138	1,40,391	1,38,142	1,42,710	1,41,799	1,46,918	1,37,946	1,42,274	1,39,016

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	74.25%	74.11%	74.07%	72.13%	72.12%	67.13%	59.31%	51.60%	49.09%	49.09%
	4.55%	5.45%	4.74%	4.85%	3.10%	2.89%	2.78%	5.49%	6.82%	7.09%
	2.71%	4.99%	2.55%	0.24%	0.09%	0.09%	0.22%	4.82%	10.58%	10.96%
	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.01%	0.02%	0.04%
	18.49%	15.45%	18.64%	22.78%	24.69%	29.89%	37.70%	38.06%	33.50%	32.84%
No. of Shareholders	1,24,403	99,736	1,14,338	1,17,324	1,25,488	1,72,460	1,82,493	1,46,138	1,41,799	1,39,016

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

All

Annual reports

Right Issue

Credit ratings

Concalls

Jun 2026

Transcript

AI Summary
PPT
Jun 2025
Transcript PPT
Jun 2025

Transcript

AI Summary
PPT
Feb 2025

Transcript

AI Summary
PPT
Oct 2024

Transcript

AI Summary
PPT
Feb 2024

Transcript

AI Summary
PPT
Feb 2023
Transcript PPT
Mar 2022

Transcript

AI Summary
PPT